Tessera: engineering mobile genetic elements for gene insertion

Tessera Therapeutics, the latest company to emerge from Flagship Pioneering, is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations than CRISPR.

The company came out of stealth on Tuesday with over $50 million in funding from Flagship, two years of research supporting its Gene Writing platform and a team of genetic engineering veterans. ...